Protein / target
T-cell surface glycoprotein CD3 gamma chain
Protein at a glance
Biological role
Signaling receptor complex adaptor
Strongest disease association
combined immunodeficiency due to CD3gamma deficiency
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response.
View complete UniProt function annotationHide complete annotation
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:2470098). In addition to this role of signal transduction in T-cell activation, CD3G plays an essential role in the dynamic regulation of TCR expression at the cell surface (PubMed:8187769). Indeed, constitutive TCR cycling is dependent on the di-leucine-based (diL) receptor-sorting motif present in CD3G
Subcellular location
Domains and Gene Ontology detail (21)Hide
Domains & features
Gene Ontology
- Calpha-beta T cell receptor complex
- Cclathrin-coated endocytic vesicle membrane
- Cexternal side of plasma membrane
- Cplasma membrane
- Fidentical protein binding
- Fsignaling receptor complex adaptor activity
- FT cell receptor binding
- Ftransmembrane signaling receptor activity
- Padaptive immune response
- Palpha-beta T cell activation
- Pcell surface receptor signaling pathway
- Pestablishment or maintenance of cell polarity
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Immune signalling
- ·Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential…
- ·alpha-beta T cell receptor complex
- ·T cell receptor binding
- ·adaptive immune response
View underlying pathways (13)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
11 medicines meet Open Targets' target-level approved-medicine definition; the 7 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
T cell surface glycoprotein CD3 cross-linking agent
Indicated for Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms
T cell surface glycoprotein CD3 binding agent
Indicated for Lymphoma, Large B-Cell, Diffuse, Neoplasms
T cell surface glycoprotein CD3 cross-linking agent
Indicated for Neoplasms
T cell surface glycoprotein CD3 binding agent
Indicated for Multiple Myeloma, Neoplasms
T cell surface glycoprotein CD3 binding agent
Indicated for Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Neoplasms
T cell surface glycoprotein CD3 binding agent
Indicated for Multiple Myeloma, Neoplasms
View all 7 targeting drugsHide
T cell surface glycoprotein CD3 binding agent
Indicated for Multiple Myeloma, Neoplasms
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene CD3G
Gene-level evidence surfaced through the gene CD3G that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
16 compounds recorded · 11 approved · 5 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Emerging
Antibodies — Strong
Protein degraders — Emerging
View underlying tractability evidence (7)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Trial status changed
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin, With or Without Glofitamab, With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (PERCH) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas
- Trial status changed
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Patients With B-Cell Non-Hodgkin Lymphoma
- Trial status changed
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
- Trial status changed
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- Trial status changed
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Label change
Label change: GLOFITAMAB (BLA761309)
- Label change
Label change: EPCORITAMAB-BYSP (BLA761324)
- Label change
Label change: GLOFITAMAB (BLA761309)
- Indication expanded
Indication expansion: EPCORITAMAB-BYSP (BLA761324)
- Indication expanded
Indication expansion: EPCORITAMAB-BYSP (BLA761324)
- New publicationThe BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
- New publicationBlinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.